
Sign up to save your podcasts
Or


Send us a text
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at sessions covering epidemiology, public response and clinical questions.
Paris NASH is a meeting for basic science and interdisciplinary thinking. As Jörn Schattenberg reviews the first two sessions of the meeting, he covers both these territories. The first session started with Professor Jeffrey Lazarus discussing some of the same issues he covered as our guest on S2 E40 of SurfingNASH. The other presentations in the first session covered economic theory and automated care models, which led Stephen Harrison to share his own thoughts on the importance of building an integrated model for clinical trials. The second session of Paris NASH discussed clinical aspects of disease. Jörn focused on a paper discussing how NASH itself varies among different patient phenotypes and what that could imply in terms of diagnostics, patient treatment and drug development.
By SurfingNASH.com3.9
2424 ratings
Send us a text
Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from last week's Paris NASH meeting. This conversation looks at sessions covering epidemiology, public response and clinical questions.
Paris NASH is a meeting for basic science and interdisciplinary thinking. As Jörn Schattenberg reviews the first two sessions of the meeting, he covers both these territories. The first session started with Professor Jeffrey Lazarus discussing some of the same issues he covered as our guest on S2 E40 of SurfingNASH. The other presentations in the first session covered economic theory and automated care models, which led Stephen Harrison to share his own thoughts on the importance of building an integrated model for clinical trials. The second session of Paris NASH discussed clinical aspects of disease. Jörn focused on a paper discussing how NASH itself varies among different patient phenotypes and what that could imply in terms of diagnostics, patient treatment and drug development.

32,309 Listeners

30,778 Listeners

9,758 Listeners

104 Listeners

21,256 Listeners

3,378 Listeners

113,432 Listeners

56,986 Listeners

9,576 Listeners

8,685 Listeners

10,279 Listeners

6,472 Listeners

0 Listeners

419 Listeners

683 Listeners